This novel study from the NEJM investigates the outcome of dual antiplatelet therapy and in-stent thrombosis
Traditional guidelines have suggested that dual antiplatelets should continue for 12 months when a cardiac drug eluting stent has been placed. This New England Journal of Medicine study evaluates the outcomes of nearly 10,000 patients with drug eluting stents in situ. The study suggests a lowered rate of in-stent thrombosis if dual antiplatelets are continued after 12 months.
Time for a re-think about timing of antiplatelet therapy?